Revolution Medicines, Inc.RVMD
NasdaqGS•Healthcare•Biotechnology
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. (RVMD) reported trailing twelve months revenue of $0 as of March 2026, a NaN% decline year-over-year. Quarterly revenue reached $0, reflecting a contraction in sales.
Revolution Medicines, Inc. reported a TTM net loss of $1.37B, with quarterly EBITDA of $-442.88M. The operating margin contracted from -24076000000.0% to -44522200000.0%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (-44522200000.0%) and net margin (-45381600000.0%) indicates significant non-operating expenses or interest burden. Net margin has narrowed from -21341600000.0% a year ago, reflecting increased costs or interest expense.
RVMD trades at a P/S of N/A. The price-to-book ratio of 12.2x indicates a significant premium over book value.
The company reported negative free cash flow of $-355.70M, indicating cash consumption over the period. The balance sheet shows $2.25B in total assets with no in long-term debt against $1.50B in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are under pressure, averaging -27203200000.0%. The business may lack pricing power or face rising costs.'
ROE is low or negative, suggesting limited competitive advantage or capital allocation challenges.
Only 0 of the last 8 quarters had positive FCF — the business may require external capital to sustain operations.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 21 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
Limited debt-to-equity data available.
TTM revenue has contracted 100.0% — significant decline indicating deteriorating demand.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 20.0% — significant dilution, likely from stock compensation or capital raises.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation